Paul Matteis
Stock Analyst at Stifel
(3.40)
# 984
Out of 5,048 analysts
117
Total ratings
45.57%
Success rate
5.76%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $174 → $183 | $141.96 | +28.91% | 10 | Oct 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $91 → $73 | $52.85 | +38.13% | 10 | Oct 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $441 → $495 | $434.07 | +14.04% | 15 | Oct 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $43 → $67 | $73.65 | -9.03% | 6 | Oct 6, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Buy | $27 | $16.17 | +66.98% | 1 | Oct 6, 2025 | |
| PEPG PepGen | Maintains: Buy | $9 → $12 | $4.53 | +164.90% | 3 | Sep 25, 2025 | |
| QURE uniQure | Maintains: Buy | $30 → $65 | $34.29 | +89.56% | 2 | Sep 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $426.00 | +6.81% | 19 | Aug 5, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $24.11 | +49.32% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $113.74 | -17.36% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $6 → $2 | $3.01 | -33.55% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $36.06 | -11.26% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $13.53 | +136.51% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.95 | +84.87% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.44 | +177.78% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $12.17 | -17.83% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $31.06 | +93.17% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $30.17 | +19.32% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.94 | +29.92% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $22.37 | -6.12% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $10.65 | +172.30% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $151.44 | +89.51% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.04 | +121.24% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.24 | +183.02% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $4.18 | +1,097.60% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $10.80 | +196.30% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.18 | +1,138.53% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $18.92 | -26.00% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $8.31 | +670.16% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $102.73 | +230.96% | 1 | Dec 21, 2016 |
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $174 → $183
Current: $141.96
Upside: +28.91%
BioMarin Pharmaceutical
Oct 28, 2025
Maintains: Buy
Price Target: $91 → $73
Current: $52.85
Upside: +38.13%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Buy
Price Target: $441 → $495
Current: $434.07
Upside: +14.04%
Ionis Pharmaceuticals
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $73.65
Upside: -9.03%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Buy
Price Target: $27
Current: $16.17
Upside: +66.98%
PepGen
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $4.53
Upside: +164.90%
uniQure
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $34.29
Upside: +89.56%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $426.00
Upside: +6.81%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $24.11
Upside: +49.32%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $113.74
Upside: -17.36%
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $3.01
Upside: -33.55%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $36.06
Upside: -11.26%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $13.53
Upside: +136.51%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.95
Upside: +84.87%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.44
Upside: +177.78%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $12.17
Upside: -17.83%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $31.06
Upside: +93.17%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $30.17
Upside: +19.32%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.94
Upside: +29.92%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $22.37
Upside: -6.12%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $10.65
Upside: +172.30%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $151.44
Upside: +89.51%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $9.04
Upside: +121.24%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.24
Upside: +183.02%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $4.18
Upside: +1,097.60%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $10.80
Upside: +196.30%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.18
Upside: +1,138.53%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $18.92
Upside: -26.00%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $8.31
Upside: +670.16%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $102.73
Upside: +230.96%